What Дротаверин Treats: Main Uses and Benefits

Дротаверин (Drotaverine) is used in the symptomatic treatment of various conditions where muscle spasms cause pain and discomfort. It is applicable within clinical settings that involve acute or disruptive symptom patterns, offering support that helps ease the overall symptom burden. It is primarily applied in addressing symptom clusters that may become intense or disruptive, particularly those linked to organ-specific functional stress.

The compound is commonly used for managing symptoms related to physical discomfort in the gastrointestinal tract. This compound is considered relevant for easing symptoms associated with conditions involving smooth muscles in the gastrointestinal, biliary, urinary, and reproductive systems. The medicine is relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden, such as conditions associated with symptoms of acute or episodic changes, including renal colic, biliary colic, functional gastrointestinal disorders (like Irritable Bowel Syndrome), and painful menstruation (dysmenorrhea).

This supportive role contributes to improved comfort during periods of heightened symptoms. The general goal is to help maintain a sense of stability when symptoms are more noticeable, assisting with functional stability.

---

Quick Fact: Relief for Smooth Muscle Spasms

Regulatory References

1. Swissmedic Public Summary for Spaverin®

The eligibility for using Drotaverine is defined by strict prohibitions and restrictions set by regulatory authorities.

Eligibility Scope

Classification	Status/Restriction	Population Group
Contraindicated	Must not be used	Patients with severe hepatic insufficiency or severe renal insufficiency.
Contraindicated	Must not be used	Patients with cardiac insufficiency (specifically low output syndrome).
Contraindicated	Must not be used	Individuals with known hypersensitivity to the active substance or excipients.
Contraindicated	Below 6 years (Use not established)	Children below 6 years of age.
Not Recommended	Use is advised against	Women who are breastfeeding.
Caution Required	Restricted use	Elderly patients, and patients with hypotension (low blood pressure).
Caution Required	Restricted use	Patients with impaired renal or hepatic function (non-severe).
Allowed	Standard approved use	Adults and adolescents above 12 years of age without contraindications.

Eligibility Classifications (High-Level)

• Eligibility severity classification (as defined in official documents): Contraindicated (absolute prohibition), Not Recommended (strong avoidance), and Caution (conditional use with monitoring).
• Regulatory basis: The criteria are formalized in the Summary of Product Characteristics (SmPC) used by national medicines agencies.

Resulting Eligibility Structure

Official eligibility statements confirm that use is strictly prohibited for those with severe organ failure (cardiac, hepatic, or renal) and for children under 6 years old. Use is further not recommended during lactation, and caution is mandated for individuals with existing hypotension or non-severe organ impairment. These classifications define who is categorically excluded versus who is conditionally eligible to use the medicine.

Interactions with other medicines and products

This section details specific, officially documented interactions of drotaverine with other medicinal products and substance categories, based strictly on authoritative governmental regulatory documents.

Documented Pharmacological Interactions

Interacting Product Category	Specific Interacting Medicine	Interaction Constraint
Dopaminergic Drugs	Levodopa	Use is strongly discouraged or requires special caution

Official Interaction Profile

The primary and most clinically significant interaction documented in regulatory labeling is with levodopa. Drotaverine may reduce the anti-parkinsonian effect of levodopa. This potential interaction can lessen the therapeutic efficacy of levodopa, which is critical for managing the motor symptoms of Parkinson's disease. Consequently, official warnings advise that concomitant use of drotaverine with levodopa should be avoided or undertaken with extreme caution and professional medical oversight.

Furthermore, when drotaverine is used alongside other medicines that inhibit phosphodiesterase (PDE) enzymes, there is a theoretical potential for the effects of drotaverine to be intensified. While this is noted as a possibility, it is generally considered a low-level interaction not resulting in specific, mandatory restrictions on its own. Patients should always inform their healthcare provider of all prescription medications, non-prescription medicines, and supplements being taken prior to initiating therapy.

️ How Дротаверин Works

Drotaverine is a musculotropic antispasmodic agent that acts directly on smooth muscle cells, independent of the autonomic nervous system, through a precise molecular cascade. Its mechanism is almost exclusively peripheral, with minimal central nervous system activity.

---

Direct Inhibition of the PDE4 Enzyme

The primary mechanism involves the selective inhibition of Phosphodiesterase 4 ( PDE4), a key enzyme found in smooth muscle. Blocking PDE4 prevents the degradation of the signaling molecule cyclic adenosine monophosphate ( cAMP), causing its intracellular concentration to rise. The resulting increase in cAMP activates cascades that lead to the reduction of free intracellular calcium ions ( Ca^2+).

---

Regulation of Cellular Calcium for Spasmolysis

The diminished level of free Ca^2+ within the smooth muscle cell functions as the final common step for smooth muscle disengagement. Since Ca^2+ is essential for muscle contraction, its reduction results in disengagement and lengthening of the muscle fibers (spasmolysis). This effect is reinforced by the drug's secondary action as an inhibitor of L-type calcium channels, further restricting Ca^2+ influx and resulting in direct relaxation of the visceral and vascular smooth musculature.

Drotaverine is administered through two primary, officially sanctioned methods: the oral route using tablets and the parenteral route (intramuscular or intravenous injection) using a solution.

Oral Administration

The standard oral dosage for adults is typically in the range of 120 mg to 240 mg of drotaverine hydrochloride per day, which is usually administered in two to three divided doses. The tablets are intended to be swallowed with water. For children between 6 and 12 years of age, the maximum recommended daily oral dose is usually restricted to 80 mg in two divided doses. Adolescents over 12 years of age may be administered up to 160 mg per day, divided into 2 to 4 doses.

Parenteral Administration

Injection is typically reserved for use in acute situations or when oral administration is not possible. The dose administered parenterally (IM or IV) usually ranges from 40 mg to 80 mg per injection, with the total daily dose generally not exceeding 240 mg. The injectable form may be administered up to three times daily. When administered intravenously, the injection must be performed slowly, often over a period of 3 to 5 minutes, and the patient should remain in a supine position during and immediately after the procedure.

Duration and Adjustments

Usage is generally indicated for the short-term management of acute episodes. The overall duration of use is guided by the resolution of symptoms. Official labeling recommends cautious use in patients with renal or hepatic impairment.

Research Evidence: Overview of Studies for Drotaverine

---

Studies for Outcomes Related to Acute Digestive and Urinary Tract Discomfort

Research has explored this substance in relation to physical discomfort outcomes. It was studied for conditions characterized by fluctuating or episodic manifestations, such as those related to the digestive system, including the biliary tract, and the urinary tract. Research examined conditions where functional stress is present. The research was used in clinical and observational settings evaluating daily-life functioning.

In studies conducted during periods of increased symptom activity, the data show patterns related to outcomes related to physical discomfort. Research highlights measured changes in outcomes describing episodic or acute changes.

However, the evidence is limited, and follow-up durations were restricted to short time intervals. Sample sizes were modest in several studies, and the certainty remains low regarding the full spectrum of outcomes. These findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

---

Research on Outcomes Related to Menstrual Discomfort

Studies explored outcomes related to physical discomfort that occur during the menstrual cycle. Studies examined symptom patterns and monitored patient-reported experiences. Studies monitored patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in these studies where changes were measured in patient-reported outcomes related to daily functioning or activity level during phases of acute changes. Research provides insight into short-term changes in symptoms where discomfort becomes more noticeable.

It is important to note that findings were mixed across the full body of evidence, and comparative evidence against other interventions is lacking. Study results reflect the specific conditions under which they were conducted, and evidence quality varies across studies. Data for certain groups remain insufficient, and research does not determine whether an individual will respond similarly.

---

Evidence in Contexts of Labor and Delivery

Research examined the use of the substance in specific research scenarios, particularly in contexts related to labor and delivery, which involve conditions presenting with cycles of stability and flare-ups. These studies focused on episodes where symptoms become more noticeable and monitored physiological strain or stress.

Research has explored outcomes linked to acute physiological changes in relation to the process of childbirth. Findings describe patterns observed in the studies related to short-term change, but certainty remains low.

Long-term effects are not fully established, and the results apply only to the populations studied. Studies contribute to the broader evidence landscape, but they highlight what is known and what is still uncertain.

Key Studies & References

1. Efficacy and safety of combination therapy with drotaverine and ketorolac versus ketorolac monotherapy for acute renal colic: a retrospective study of 322 patients (Zhu et al.)
2. The Influence of Oral Drotaverine Administration on Materno–Fetal Circulation during the Second and Third Trimester of Pregnancy (Kubiak et al.)

Common questions about Дротаверин (FAQ)

---

Q: How quickly does Дротаверин start working after taking it?

A: Official product information, based on pharmacokinetic data, suggests that the medicine may begin its effect approximately 30 minutes after oral administration. This time frame reflects how quickly the effects may begin.

---

Q: What is the difference between Дротаверин and No-Spa?

A: There is no difference in the active ingredient; No-Spa is actually one of the widely recognized trade names for the pharmaceutical compound, Drotaverine (drotaverine hydrochloride). They refer to the same musculotropic antispasmodic medication.

---

Q: How long do the effects of Дротаверин usually last?

A: Based on regulatory pharmacokinetic studies, the effects of a single dose are generally reported to last for approximately 4 hours. This duration is part of the overall pharmacokinetic profile of the medicine.

---

Q: Is it safe to take Дротаверин with alcohol?

A: Regulatory warnings sometimes advise caution regarding this combination. Consuming alcohol may potentially increase or worsen some of the documented side effects of the medicine.

---

Q: Is Дротаверин considered safe to use during pregnancy for certain conditions?

A: Official regulatory information generally advises that the use of Drotaverine should be avoided during pregnancy. Decisions about using the medicine during pregnancy must be made by a healthcare professional after carefully evaluating the necessity.

---

Q: What should I do if a side effect from Дротаверин seems unusual or severe?

A: Official safety documents emphasize that if a patient experiences side effects that persist, become severe, or if signs of a serious allergic reaction occur, it is advised to contact a healthcare professional or emergency services promptly.

---

Q: Does Дротаверин work for spasms in both skeletal and smooth muscles?

A: Drotaverine is specifically classified as a musculotropic antispasmodic with a pronounced action only on smooth muscles, such as those in internal organs and blood vessels. It is not known to target spasms in the skeletal muscles, which are those responsible for movement.

---

Q: What happens if you miss a dose of Дротаверин?

A: Official prescribing information contains specific instructions for what to do when a dose is missed. It generally advises against taking a double dose to compensate for the forgotten one.

---

Q: Is Дротаверин available without a prescription in some countries?

A: The availability of this drug varies by region. In some countries, regulatory bodies have designated the tablet form as available Over-the-Counter (OTC). The availability of the injectable form is generally subject to prescription requirements.

---

Q: Does taking Дротаверин affect the ability to drive or operate machinery?

A: Official product information notes that certain side effects, such as dizziness and vertigo (a spinning sensation), may occur. Patients experiencing these effects should avoid driving or operating machinery until the effects subside.

---

Q: Is it possible to take Дротаверин on an empty stomach?

A: According to the product information in official regulatory documents, this medicine can generally be administered with or without food.

---

Q: How does the structure of the Дротаверин molecule relate to its function?

A: Drotaverine is chemically known as a benzylisoquinoline derivative, which means its structure is similar to that of Papaverine. This chemical class is associated with its ability to act as a smooth muscle relaxant and antispasmodic agent.

---

Q: Can people with lactose intolerance take the tablet form of Дротаверин?

A: Official regulatory documents confirm that the tablet formulation of this medication contains the inactive ingredient Lactose Monohydrate. Patients with known or suspected lactose intolerance should be aware of this excipient.

---

How to Store and Dispose of Drotaverine

Drotaverine must be stored under specific environmental and packaging conditions to maintain its stability until the expiration date.

Storage Requirements

Official labeling requires that this medicine be stored at a temperature not exceeding 30, C. The product must be protected from light and moisture and stored in a cool, dry place. To maintain product integrity, it must be kept in the original packaging (or outer carton) until use. For safety, Drotaverine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Drotaverine must be discarded in accordance with local requirements. Official guidelines typically advise that medicines should not be disposed of via wastewater or household waste, unless specific local instructions are provided.